Clinical Trial: Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
Sponsor and Collaborators
Assistance Publique – Hôpitaux de Paris
Contact: Zakia Idir, PhD
+33 1 4484 1747
Celeste Lebbe, MD, PhD Hôpital Saint-Louis, Paris, France
Next post in Melanoma Clinical Trials
Log in to continue reading this article.
Don’t miss out on today’s top content on Oncology Nurse Advisor. Register for free and gain unlimited access to:
- Clinical Updates
- Evidence-Based Guidance
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
Want to read more?
Please login or register first to view this content.